[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594991":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":24,"centralContacts":28,"locations":23,"responsibleParty":38,"collaborators":23,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":23,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":23,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":62,"whyStopped":23,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":23},{"fullName":5,"class":6},"University of Calgary","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"active aVNT","EXPERIMENTAL","For rigorous mechanistic evaluation and to establish causal relationships, intervention strategies (active aVNT vs. Sham) will be randomized among participants in this mechanistic study, ensuring that observed physiological effects are attributable to aVNT rather than placebo effects, baseline variability, or confounding factors. Patients with POTS will be randomly assigned to 3 months of active aVNT or sham treatment in 1:1 ratio. Patients will continue their stable ongoing non-pharmacological and pharmacological treatments for POTS. We will perform in-laboratory evaluations at baseline and 3 months post-randomization. We will also collect data on HR and orthostatic tachycardia at home in between the laboratory evaluations, using a wearable monitor.",[13],"Device: active aVNT vs. Sham",{"label":15,"type":10,"description":11,"interventionNames":16},"Sham",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DEVICE","active aVNT vs. Sham","Patients in both groups will receive daily stimulation with the Parasym device, temporarily connected to the tragus of the right ear (Fig 2).54 The stimulation parameters will be frequency of 20 Hz, pulse width of 200 µs, and the stimulation amplitude will be titrated to 1 mA below the discomfort threshold, consistent with parameters used in published clinical studies.54-56 With this stimulation at just below the discomfort threshold, people will often feel the stimulation for less than 60 seconds before they lose awareness of the ongoing stimulation. The stimulation will continue for 1 hour daily for 3 months, and we will track its use with a patient diary. Participants can continue their regular activities while wearing the aVNT device, as long as it is not soaked in water. Parasym will obtain Health Canada approval for use of their device in the study.",[15,9],null,[25],{"name":26,"affiliation":5,"role":27},"Satish Raj, MD","PRINCIPAL_INVESTIGATOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":23,"email":33},"Jiyao Qi, MD","CONTACT","14032107627","jiyao.qi@ucalgary.ca",{"name":35,"role":31,"phone":36,"phoneExt":23,"email":37},"Rasha Hamzeh, RN, MSN","4032208897","rasha.hamzeh1@ucalgary.ca",{"type":39,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100594991","avnt-in-pots---pilot-100594991",false,"NCT07026643","aVNT in POTS - Pilot","Auricular Vagal Neuromodulation Therapy in Postural Orthostatic Tachycardia Syndrome: Physiological Mechanisms and Systemic Effects - A Pilot Study","Inclusion Criteria:\n\n* POTS Patients: POTS patients will meet Canadian Cardiovascular Society criteria. 6 POTS patients will have orthostatic tachycardia \\>30 bpm increase in HR within 10 minutes of upright posture \\[\\>40 bpm in patients \\\u003C20 years\\]), in the absence of orthostatic hypotension (drop in BP \\>20\u002F10 mmHg), chronic symptoms of orthostatic intolerance, and no obvious cause for the tachycardia.\n* Age between 18-80 years\n* Male and female subjects are eligible\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Unable to give informed consent\n* Stimulant use within one week of the study\n* Systolic blood pressure \\>150 mm Hg and\u002For diastolic blood pressure \\> 100 mm Hg\n* Neurogenic orthostatic hypotension, prior stroke, myocardial infarction or heart failure, hematocrit \\\u003C 28%\n* Significant comorbidities (cardiovascular, metabolic, renal, respiratory, cancer, immunological or hematological)\n* History of vagotomy, permanent pacemakers\n* Pregnant or nursing females.","ALL","18 Years","80 Years",{"count":51,"type":52},30,"ESTIMATED","INTERVENTIONAL",[55],"NA","Autonomic nervous system imbalance causes postural tachycardia and related cardiac symptoms in Postural Orthostatic Tachycardia Syndrome (POTS). The impact of POTS is more far-reaching than postural tachycardia. Several systemic, autonomic symptoms along with neuro-cognitive dysfunction leading to poor quality of life contribute to significant disability in POTS. A combination of abnormal autonomic tone, abnormal cerebral blood flow regulation, and systemic inflammation may contribute to POTS symptoms.\n\nAuricular Vagal Neuromodulation Therapy (aVNT) has the potential for multisystem holistic benefit for patients with POTS: Autonomic neuromodulation by aVNT might address multiple aspects of POTS pathophysiology and improve POTS symptoms. It can reduce postural tachycardia by increasing the parasympathetic (PNS) and decreasing sympathetic (SNS) tone. In patients undergoing vagus nerve stimulation for various indications, an increase in PNS tone has been associated with improved middle cerebral artery velocity (MCAv) at rest and during cognitive stress. aVNT has been associated with improved cerebral blood flow and reduced infarct size in an experimental model of ischemic stroke, suggesting similar improvements in cerebral autoregulation in POTS. Vagus nerve stimulation has also been linked to improved cognitive function. The anti-inflammatory effect and improved endothelial function might improve cerebral blood flow regulation and cognitive function. The anti-inflammatory effects of aVNT may improve postural hemodynamics, reduce postural tachycardia, relieve other POTS symptoms, and improve quality of life (QoL). POTS is a complex multisystem disorder with debilitating symptoms that currently lack effective treatments. aVNT has the potential to recalibrate autonomic tone dysregulation, enhance MCAv, improve cognitive function, reduce inflammation, and ultimately improve symptoms and quality of life in POTS patients.",[58],"Postural Orthostatic Tachycardia Syndrome (POTS)",[60,61],"Postural Orthostatic Tachycardia Syndrome","Auricular vagal neuromodulation therapy","NOT_YET_RECRUITING","2026-04-30",{"date":65,"type":66},"2026-05-01","ACTUAL",{"date":68,"type":52},"2026-09-01",{"date":70,"type":52},"2031-12-31",{"name":5,"class":6}]